CAIClinical Trials•prnewswire•August 15, 2025 at 12:30 PM

Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®

Sentiment:Positive (70)

Summary

IRVING, Texas, Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek®. This...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 15, 2025 by prnewswire